{"url_path":"/sec/mtnb/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1582554/0001493152-26-022010-index.html","accession_number":"0001493152-26-022010","cik":"0001582554","ticker":"MTNB","issuer_name":"Matinas BioPharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1582554/0001493152-26-022010-index.html","primary_entity_key":"0001582554","primary_entity_name":"Matinas BioPharma Holdings, Inc."},"word_count":55,"has_tables":true,"body_markdown":"**Item\n5. OTHER INFORMATION.**\n\n \n\n*Rule\n10b5-1 Trading Arrangements and Non-Rule 10b5-1 Trading Arrangements*\n\n \n\nDuring\nthe fiscal quarter ended March 31, 2026, none of our officers or directors, as those terms are defined in Rule 16a-1(f), adopted or terminated\na “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in"}